Wells Fargo & Company MN Has $974,000 Position in Lantheus Holdings, Inc. (LNTH)
Wells Fargo & Company MN raised its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 7,781.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,173 shares of the medical equipment provider’s stock after buying an additional 54,473 shares during the quarter. Wells Fargo & Company MN owned about 0.15% of Lantheus Holdings worth $974,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also bought and sold shares of LNTH. Bank of New York Mellon Corp grew its position in Lantheus Holdings by 6.3% during the first quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock worth $856,000 after buying an additional 4,084 shares in the last quarter. Parametric Portfolio Associates LLC grew its position in Lantheus Holdings by 28.9% during the first quarter. Parametric Portfolio Associates LLC now owns 22,530 shares of the medical equipment provider’s stock worth $282,000 after buying an additional 5,058 shares in the last quarter. California Public Employees Retirement System grew its position in Lantheus Holdings by 29.2% during the first quarter. California Public Employees Retirement System now owns 77,800 shares of the medical equipment provider’s stock worth $973,000 after buying an additional 17,600 shares in the last quarter. Vanguard Group Inc. grew its position in Lantheus Holdings by 7.0% during the first quarter. Vanguard Group Inc. now owns 788,396 shares of the medical equipment provider’s stock worth $9,855,000 after buying an additional 51,590 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in Lantheus Holdings during the first quarter worth about $3,646,000. Institutional investors and hedge funds own 85.03% of the company’s stock.
Lantheus Holdings, Inc. (NASDAQ:LNTH) opened at $22.30 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $23.00. The company has a quick ratio of 2.43, a current ratio of 2.92 and a debt-to-equity ratio of -3.05. The stock has a market capitalization of $836.38, a PE ratio of 19.91, a PEG ratio of 1.63 and a beta of 0.92.
Lantheus Holdings (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.04. Lantheus Holdings had a negative return on equity of 44.05% and a net margin of 9.59%. The firm had revenue of $79.94 million during the quarter, compared to analysts’ expectations of $77.18 million. During the same period in the prior year, the business earned $0.15 EPS. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. research analysts anticipate that Lantheus Holdings, Inc. will post 1.1 earnings per share for the current fiscal year.
Several research firms recently commented on LNTH. Jefferies Group LLC restated a “buy” rating and set a $22.00 target price (up from $18.00) on shares of Lantheus Holdings in a research report on Wednesday, August 2nd. Zacks Investment Research cut Lantheus Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, September 20th. Credit Suisse Group boosted their target price on Lantheus Holdings from $19.00 to $23.00 and gave the stock a “neutral” rating in a research report on Friday. Cantor Fitzgerald began coverage on Lantheus Holdings in a research report on Monday, July 17th. They set an “overweight” rating and a $22.00 target price for the company. Finally, Wells Fargo & Company upgraded Lantheus Holdings from a “market perform” rating to an “outperform” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $20.40.
In other news, insider Michael P. Duffy sold 20,000 shares of the company’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $16.45, for a total value of $329,000.00. Following the completion of the transaction, the insider now directly owns 184,218 shares in the company, valued at approximately $3,030,386.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Avista Capital Partners Gp, Ll sold 87,939 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $17.40, for a total value of $1,530,138.60. The disclosure for this sale can be found here. Insiders sold a total of 903,099 shares of company stock valued at $15,443,485 over the last quarter. Company insiders own 2.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/wells-fargo-company-mn-has-974000-position-in-lantheus-holdings-inc-lnth/1679677.html.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH).
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.